Aparna Goel, MD

Future Advancements in PBC Care: Innovations on the Horizon

In the final episode, “Future Advancements in PBC Care: Innovations on the Horizon,” the panelists explore current gaps in care and new treatments that are trying to close those gaps.

Led by the moderator, the panelists examine the following critical questions:

Looking ahead towards the future of primary biliary cholangitis care, what ongoing trials or emerging treatments do you feel are promising or practice-changing?

What is one final pearl you would like to share about the management of primary biliary cholangitis and the future ahead?

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Thank you for watching this Peer Exchange series on PBC. Please subscribe to our newsletter for information on upcoming video series.

Videos

New Fatigue Signals From Elafibranor: Results From the ELATIVE Phase III Trial

This episode, titled “New Fatigue Signals From Elafibranor: Results From the ELATIVE Phase III Trial” features panelists discussing highlighting recent data on elafibranor and how changes in fatigue/pruritus were largely independent from biomarker changes. Clinicians then discuss how this information may impact future treatment decisions.

Led by the moderator, the experts examine the following critical questions:

Results announced from EASL and AASLD this year revealed that changes in fatigue and pruritus for patients on elafibranor from the phase III ELATIVE trial were largely independent from biomarker changes. Can you expand upon the clinical significance of these findings, especially for patients with severe symptomatic burden?

Looking ahead, how can clinicians utilize this information to make targeted treatment decisions?

In the final episode, “Future Advancements in PBC Care: Innovations on the Horizon” panelists will continue their discussion on PBC and highlight investigational

New studies reveal potential benefits of alfagimor in reducing fatigue and pruritus, highlighting its role in second-line therapy for patients.

Addressing Fatigue: Traditional Management Outside Primary Therapy

In this episode, experts delve into the limited treatment options to address the symptom of fatigue in patients with primary biliary cholangitis. They highlight how small changes, like regular sleep schedules and exercise, can improve fatigue.

How have clinicians historically treated symptoms of fatigue? Please describe your treatment approach and how it may differ between moderate and severe cases of primary biliary cholangitis.

Without a remedy for fatigue, how do you educate and coach patients with severe fatigue on managing their symptoms?

Our next episode, “New Fatigue Signals From Elafibranor: Results From the ELATIVE Phase III Trial” further explores PBC, highlighting recent data on elafibranor and how changes in fatigue/pruritus were largely independent from biomarker changes.

The Safety of PPAR Agonists in PBC: Reviewing Recent Trial Data

In this episode, “The Safety of PPAR Agonists in PBC: Reviewing Recent Trial Data” the expert hepatologists explore key safety data from the ELATIVE trial on elafibranor and from RESPONSE on seladelpar.

Led by the moderator, the panelists examine the following critical question:

What have we learned about the safety of PPAR agonists from the primary trials of elafibranor (ELATIVE) and seladelpar (RESPONSE)?

The next episode in this series, “Addressing Fatigue: Traditional Management Outside Primary Therapy,” features the panelists advancing their conversation on PBC and focusing on how they typically manage patient fatigue beyond primary therapies. They discuss how to coach patients into beneficial health and wellness routines to reduce fatigue, and stress the importance of a regular sleeping schedule.

Explore the safety and long-term effects of PPAR agonists in patients with liver disease, addressing concerns about bone health and medication interactions.

Aparna Goel, MD

Articles